Daily Cardiology Research Analysis
Analyzed 232 papers and selected 3 impactful papers.
Summary
Three impactful studies advance cardiology practice: a secondary analysis of the SOUL randomized trial shows oral semaglutide reduces heart failure events in people with type 2 diabetes who have preexisting heart failure; a prespecified 3-year analysis of the LYTEN randomized trial finds self-expanding valves provide superior hemodynamics versus balloon-expandable valves in valve-in-valve TAVR for failed small surgical bioprostheses; and an international registry analysis suggests intra-aortic balloon pump use may lower in-hospital mortality in takotsubo syndrome with cardiogenic shock, whereas Impella does not.
Research Themes
- GLP-1 receptor agonists and heart failure event reduction in diabetes
- Device selection in valve-in-valve TAVR for small surgical bioprostheses
- Mechanical circulatory support strategies in takotsubo cardiogenic shock
Selected Articles
1. Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
In a secondary analysis of 9650 participants from the SOUL RCT, daily oral semaglutide reduced the composite of HF hospitalization/urgent HF visit/cardiovascular death in those with baseline HF (HR 0.78), driven by benefit in HF with preserved ejection fraction (HR 0.59). MACE reduction was consistent irrespective of HF history, and serious adverse events were similar to placebo.
Impact: This provides randomized evidence that a GLP-1 receptor agonist may reduce heart failure events in T2D patients with existing HF, especially HFpEF, expanding therapeutic options beyond SGLT2 inhibitors.
Clinical Implications: Consider oral semaglutide as part of cardiometabolic optimization in T2D with HF—particularly HFpEF—while continuing guideline-directed therapy; monitor for class-typical adverse effects.
Key Findings
- Among T2D participants with baseline HF, oral semaglutide reduced the composite HF outcome vs placebo (HR 0.78; 95% CI 0.63–0.96).
- Benefit was pronounced in HFpEF (HR 0.59; 95% CI 0.39–0.86) but not evident in HFrEF (HR 0.98; 95% CI 0.70–1.38).
- MACE reduction was consistent regardless of HF history (no significant interaction), and serious adverse events were similar between groups.
Methodological Strengths
- Large, double-blind, placebo-controlled, event-driven randomized trial with multinational enrollment
- Prespecified composite HF endpoint and stratification by HF history with long follow-up (~47.5 months)
Limitations
- Secondary analysis not primarily powered for HF outcomes; interaction P=0.06 for HF history
- Potential heterogeneity in HF phenotyping and background therapies
Future Directions: Prospective trials specifically targeting HF outcomes in HFpEF populations with GLP-1 RAs, head-to-head comparisons with SGLT2 inhibitors, and mechanistic studies in cardiac remodeling.
IMPORTANCE: Heart failure (HF) is a common complication of type 2 diabetes (T2D). Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D in the SOUL trial, but the impact on HF outcomes in these participants is unknown. OBJECTIVE: To evaluate the effect of oral semaglutide on HF events, MACE, and safety among participants with or without HF at baseline. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, which was conducted at 444 centers in 33 countries. Participants were enrolled from June 17, 2019, to March 24, 2021, and had T2D and atherosclerotic CV disease and/or chronic kidney disease, stratified according to the presence or absence of HF history at baseline. Data were analyzed from December 2024 to August 2025. INTERVENTION: Once-daily oral semaglutide or placebo in addition to standard of care. MAIN OUTCOMES AND MEASURES: Prespecified composite HF outcome (time to first occurrence of HF hospitalization, urgent HF visit, or CV death). RESULTS: Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 2790 [28.9%] female) were randomized, with a mean (SD) follow-up of 47.5 (10.9) months. Of these participants, 2229 (23.1%) had HF history (991 [10.3%] with preserved ejection fraction, 592 [6.1%] with reduced ejection fraction, and 646 [6.7%] with unknown subtype). For participants with HF at baseline, the hazard ratio (HR) for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96) and was 1.01 (95% CI, 0.84-1.20) in those without HF at baseline (P for interaction = .06). Among participants with HF, the HR was 0.59 (95% CI, 0.39-0.86) in those with preserved ejection fraction and 0.98 (95% CI, 0.70-1.38) in those with reduced ejection fraction. There was no heterogeneity in the risk reduction of MACE with oral semaglutide in participants with HF history (HR, 0.83; 95% CI, 0.68-1.01) or without HF history (HR, 0.86; 95% CI, 0.75-0.98) (P for interaction = .77). Serious adverse event occurrence among participants with HF was similar with oral semaglutide (594 [53.8%]) and placebo (642 [57.1%]). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the SOUL randomized clinical trial, among individuals with T2D, atherosclerotic CV disease, and/or chronic kidney disease, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a history of HF, without increasing the risk of serious adverse events. These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03914326.
2. Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial.
In this prespecified secondary analysis of the LYTEN randomized trial (n=98) of valve-in-valve TAVR for failed small surgical bioprostheses, self-expanding valves achieved markedly higher rates of intended valve performance at 3 years than balloon-expandable valves, while clinical outcomes and functional improvements were similar.
Impact: Provides randomized, mid-term comparative data informing device selection in challenging valve-in-valve TAVR for small failed bioprostheses—a frequent and clinically important scenario.
Clinical Implications: For valve-in-valve TAVR in small failed surgical valves (≤23 mm), self-expanding valves may be preferred to optimize long-term hemodynamics, while balancing other procedural considerations.
Key Findings
- Randomized comparison (SEV vs BEV) showed higher 3-year intended valve performance with self-expanding valves (82.4% vs 27.6%).
- Clinical outcomes and functional improvement at 3 years were similar between SEV and BEV groups by VARC-2/3 criteria.
- Valve-in-valve in small failed surgical bioprostheses remains feasible with both platforms, but hemodynamic durability favored SEV.
Methodological Strengths
- Randomized assignment between valve platforms with prespecified 3-year analysis
- Standardized Doppler echocardiography and VARC-2/3 endpoint definitions
Limitations
- Small total sample size (n=98) and secondary analysis not powered for hard clinical endpoints
- Device iterations and operator experience may influence generalizability
Future Directions: Larger randomized trials with clinical endpoints, assessment of coronary access and reintervention, and anatomical predictors to personalize platform choice.
BACKGROUND: Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement field have been obtained from retrospective studies. This prespecified secondary analysis of the LYTEN randomized trial (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprostheses) aims to compare the 3-year hemodynamic performance and clinical outcomes between balloon-expandable valves (BEV) SAPIEN 3/ULTRA (Edwards Lifesciences) and self-expanding valves (SEV) Evolut R/PRO/PRO+ (Medtronic) in valve-in-valve transcatheter aortic valve replacement. METHODS: Patients with a failed small (≤23 mm) surgical valve undergoing valve-in-valve transcatheter aortic valve replacement were randomized to receive a SEV or a BEV. Patients had a clinical and valve hemodynamic (Doppler echocardiography) evaluation at 3-year follow-up. Study outcomes were defined according to VARC (Valve Academic Research Consortium)-2/VARC-3 criteria. Intended performance of the valve was defined as mean gradient <20 mm Hg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate AR. RESULTS: Ninety-eight patients underwent transcatheter aortic valve replacement (46 BEV-SAPIEN 3/ULTRA-, 52 SEV-Evolut R-PRO-PRO+). At 3 years, patients receiving a SEV had a higher rate of intended valve performance (BEV: 27.6% versus SEV: 82.4%; CONCLUSIONS: In patients undergoing valve-in-valve transcatheter aortic valve replacement for failed small aortic bioprostheses, SEV demonstrated a superior valve hemodynamic performance at 3-year follow-up, with similar clinical outcomes and functional improvement compared with BEV. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03520101.
3. Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.
In takotsubo syndrome with cardiogenic shock (n=309), propensity-matched analysis showed IABP use was associated with lower in-hospital mortality versus medical therapy, whereas Impella was not and had higher complication rates. Findings suggest device-specific risk–benefit differences and support selective use of IABP.
Impact: Addresses a major evidence gap in managing TTS-related shock with comparative, propensity-matched data from an international registry, providing actionable guidance on device choice.
Clinical Implications: For TTS cardiogenic shock, consider IABP (大動脈内バルーンパンピング) preferentially when MCS is needed, and exercise caution with Impella (経皮的左心室補助装置) given higher complication rates and lack of mortality benefit in this analysis.
Key Findings
- IABP vs medical therapy only was associated with lower in-hospital mortality (14.5% vs 35.5%; P=0.002) after propensity matching.
- Impella vs medical therapy only showed no mortality benefit (25.0% vs 29.2%; P=0.75).
- MCS-related complications were more frequent with Impella (31.3%) than with IABP (6.0%).
Methodological Strengths
- Large international registry with focused cardiogenic shock subgroup
- Two separate propensity score–matched comparisons (IABP vs medical; Impella vs medical)
Limitations
- Observational design with residual confounding and selection bias
- Device selection not randomized; center/era effects may influence outcomes
Future Directions: Prospective randomized or carefully controlled pragmatic trials comparing MCS strategies in TTS shock; mechanistic studies on LV outflow tract obstruction interplay.
BACKGROUND: Cardiogenic shock complicates takotsubo syndrome (TTS) in approximately 10% of cases. The effectiveness of mechanical circulatory support (MCS) for managing cardiogenic shock in TTS remains unknown. METHODS: We assessed outcomes in TTS patients with cardiogenic shock who received MCS compared to medical therapy only by using data from the International Takotsubo Registry. Two independent propensity scores were computed to investigate outcomes of patients with an intra-aortic balloon pump (IABP) vs. medical therapy only (1:2 propensity score matched cohort) and patients with an Impella vs. medical therapy only (1:1 propensity score matched cohort). The primary endpoint was in-hospital mortality and the secondary outcomes included MCS-related complications. RESULTS: Among 3740 eligible patients, 309 (8.3%) patients had cardiogenic shock, of whom 112 (36.2%) had MCS and 197 (63.8%) had medical therapy only. After propensity-score matching, the use of an IABP was found to be associated with a lower in-hospital mortality rate than medical therapy only (14.5% vs. 35.5%, P = 0.002), while mortality rates in the Impella group and medical therapy only group were comparable (25.0% vs. 29.2%, P = 0.75). MCS-related complications occurred in 6.0% of the IABP cohort and in 31.3% of Impella cohort. CONCLUSION: Active MCS has been increasingly used for the management of cardiogenic shock in patients with TTS. This observational study could not demonstrate an association with improved mortality with an Impella device, but possibly with an IABP when compared to patients with medical management only. MCS-related complications occurred more frequently in the Impella cohort than in the IABP cohort. Further data are required to confirm results of the present study.